Public Engagement & Statements
ASCPT follows a structured process approved by the Board of Directors to determine when and how the Society should use its voice on external issues and policies. To ensure our contributions are both effective and responsible, every statement is evaluated against our core mission, vision, and values. By prioritizing scientific integrity and member impact, this framework ensures that when ASCPT speaks, it does so with the authority and evidence-based clarity necessary to advance clinical pharmacology and translational science for the benefit of patients and society.
Our Evaluation Criteria
When deciding to issue a statement or sign on to an existing policy, ASCPT leadership evaluates the situation through four primary lenses:
- Principle: Strategic Focus
- Mission-Driven: Does this advance therapeutics and translational science?
- Member-Focused: Does this strengthen the credibility of our field and our members?
- Evidence-Based: Is the stance grounded in sound science and peer-reviewed data?
- Ethical & Equitable: Does it uphold our commitment to integrity, inclusion, and fairness?
2025 Statements:
September 2025: ASCPT joins more than 90 other organizations in a coalition letter to White House OSTP Director Kratsios, emphasizing the importance of maintaining scientific integrity
June 2025: Coalition letter organized by ResearchAmerica to Congressional leaders regarding the dangers of the President’s budget proposal, signed by 500 organizations and 2355 individuals
May 2025: Coalition Letter to Congress Regarding HHS Personnel Reductions
April 2025: Coalition Statement on the Impact and Safety of Vaccines
April 2025: Statement of Support for Federal Scientists
March 2025: ASCPT Stands Firm in Support of Scientific Research Amidst Funding Challenges